Radiation Oncology

SGO 2025

Questions discussed in this category

What are your top takeaways from SGO 2025?

3 Answers available

Papers discussed in this category

Lancet (London, England), 2024 Mar 20

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.

Lancet (London, England), 2024 Oct 11

Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.

Related Topics in Radiation Oncology